Corporate

Corporate
Biotech
26/09/2022

Servier exercises the exclusive worldwide license option of their collaboration program LRRK2

CTA approval by the ANSM and the EC of the phase 1 program resulting from the collaboration between Servier and OPM for the development of an innovative treatment in Parkinson's disease...

Financial Press Release | Oncodesign
Corporate
Financial
15/09/2022

Oncodesign announces its results for the first half of 2022

28% growth in Service turnover

Meet Oncodesign in person this spring
Corporate
Service
27/04/2022

[Congress] Meet Oncodesign in person this spring

Check out where to meet Oncodesign this spring... surely we can arrange a meeting somewhere.

investors-oncodesign
Corporate
Financial
07/04/2022

Oncodesign confirms its very good results in 2021 and an attractive outlook for 2022

Read the full press release about our very good results in 2021 & an attractive outlook for 2022 for the group & our BUs Service, Biotech & AI.

Financial Result oncodesign
Corporate
Financial
27/01/2022

Oncodesign announces a 2021 turnover of €31.3M, up by 22%, and expects to break even

Find all the 2021 financial information: 2021 turnover of €31.3M, up by 22%, and expects to break even and dive into the BU financial results

Financial Agenda for 2022 - Oncodesign
Corporate
Financial
05/01/2022

ONCODESIGN announces its 2022 financial agenda

Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)

EHDEN - The European Health Data & Evidence Network - Oncodesign
Corporate
A.I
28/10/2021

Oncodesign: EHDEN Certified SME

EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.

Karine Lignel | Senior Executive Vice President - Group Chief Development Officer - Oncodesign
Corporate
Financial
25/10/2021

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.

Corporate
Financial
05/07/2021

Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors

Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.

Corporate
02/07/2021

Find out how we built our logo!

Oncodesign Find out how we built our logo! trajectory DNA innovation...green and bleue pharma colors Find out how we built our logo!